Vanda Pharmaceuticals (VNDA) Short-term Investments (2010 - 2026)

Vanda Pharmaceuticals (VNDA) has 17 years of Short-term Investments data on file, last reported at $148.3 million in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments fell 35.28% year-over-year to $148.3 million; the trailing twelve-month figure through Mar 2026 stood at $148.3 million (down 35.28% YoY), and the FY2025 full-year result was $179.0 million, down 34.27% from the prior year.
• Short-term Investments declined to $148.3 million in Q1 2026, from $179.0 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $405.4 million in Q3 2022 to a low of $147.3 million in Q1 2023.
• A 5-year average of $274.1 million and a median of $272.3 million in 2024 frame the typical range for Short-term Investments.
• Across the five-year window, Short-term Investments plunged 59.99% in 2023 and jumped 82.58% in 2024, its largest moves.
• Tracing VNDA's Short-term Investments over 5 years: stood at $331.8 million in 2022, then fell by 23.92% to $252.4 million in 2023, then grew by 7.88% to $272.3 million in 2024, then slumped by 34.27% to $179.0 million in 2025, then decreased by 17.16% to $148.3 million in 2026.
• Business Quant data shows VNDA's Short-term Investments at $148.3 million in Q1 2026, $179.0 million in Q4 2025, and $223.7 million in Q3 2025.